Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.
Mucosal administration (intranasal or oral) of a VP6 rotavirus vaccine to mice consistently elicits high levels of protection after rotavirus challenge (93->99% reductions in fecal rotavirus shedding) but only when co-administered with an effective adjuvant such as LT(R192G). Here, we showed that Biojector needle-free injection of VP6-encoded plasmids also induced protection (85-93%) when they were co-administrated with LT(R192G)-encoded plasmids. A reduction in the amount of VP6 plasmid from 50 to 10 microg reduced protection from 93 to 70%, but the immunized mice remained significantly (P<0.05) protected. Intramuscular needle injection of VP6/LT(R192G)-plasmids also induced significant protection (66%).
Choi
Anthony H-C
AH
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. anthony.choi@cchmc.org
Smiley
Kristi
K
Basu
Mitali
M
McNeal
Monica M
MM
Shao
Mingyuan
M
Bean
Judy A
JA
Clements
John D
JD
Stout
Richard R
RR
Ward
Richard L
RL
D000818:Animals; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D004279:DNA, Viral / Q000008:administration & dosage*; D004333:Drug Administration Routes; D007114:Immunization; D007271:Injections, Intradermal; D051379:Mice; D008807:Mice, Inbred BALB C; D011933:Reagent Kits, Diagnostic; D012401:Rotavirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D012400:Rotavirus Infections / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000235:genetics
D036022:Capsid Proteins; D004279:DNA, Viral; D011933:Reagent Kits, Diagnostic; D022243:Rotavirus Vaccines